Nadolol for Proliferating Infantile Hemangiomas

Inclusion Criteria: Intervention Group * Infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement. Historical Control Group * Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years Angiogenesis Marker Control Group * Infants aged 1 month to 1 year attending dermatology clinic Exclusion Criteria: Intervention Group * Patients with PHACES syndrome (proven) or suspected PHACES (plaque like hemangioma awaiting imaging). * Children with history of hypersensitivity to beta blockers * Children with personal history or family history of a first degree relative with asthma * Children with known renal impairment * Children with known cardiac conditions which may predispose to heart blocks * Personal history of hypoglycemia * Children on medications that may interact with beta blockers Historical Control Group: * No digital photography available documenting IHs progression Angiogenesis Marker Control Group: * Children with IH * Children on beta blocker or systemic corticosteroids